Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

[1]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[2]  H. Kantarjian,et al.  Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. , 1990, Cancer research.

[3]  Y Z Xu,et al.  Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. , 1990, Molecular pharmacology.

[4]  L. Hertel,et al.  Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.

[5]  W. Plunkett,et al.  Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. , 1990, Cancer research.

[6]  E. Estey,et al.  Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Hertel,et al.  Synthesis of 2-Deoxy-2,2-difluoro-D-ribose and 2-Deoxy-2,2-difluoro-D-ribofuranosyl Nucleosides. , 1988 .

[8]  V. Heinemann,et al.  Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.

[9]  L. Hertel,et al.  Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosides , 1988 .

[10]  E. Estey,et al.  Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. , 1987, Seminars in oncology.

[11]  E. Estey,et al.  Saturation of 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Accumulation in Leukemia Cells during High-Dose 1-β-d-Arabinofuranosylcytosine Therapy , 1987 .

[12]  E. Estey,et al.  Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. , 1986, The American journal of medicine.

[13]  A. Harris,et al.  Variation in Sensitivity of DNA Synthesis to Ara‐C in Acute Myeloid Leukaemia , 1980, British journal of haematology.

[14]  T. Chou,et al.  Metabolism of 1- β -d-Arabinofuranosylcytosine in Human Leukemic Cells , 1977 .

[15]  E. Estey,et al.  Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. , 1990, Leukemia.

[16]  V. Heinemann,et al.  2′,2′-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells , 1989 .

[17]  C. Haanen,et al.  In-vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells. , 1987, Leukemia research.

[18]  E. Estey,et al.  Pharmacologically directed ara-C therapy for refractory leukemia. , 1985, Seminars in oncology.